No Data
Ensysce Biosciences ENSC Patent; Rezolute RZLT Offering and Data Monitoring Committee
Rezolute 'Thrilled' With Positive Review Of Genetic Disorder Trial, Expects Topline Results In December
Rezolute Shares Are Trading Higher After the Company Announced the Data Monitoring Committee Has Recommended the Continuation of Its Phase 3 Sunrize Study.
Rezolute's Promising Clinical Developments and Positive Outlook: A Buy Recommendation by Yun Zhong
Rezolute Gets Independent DMC's Positive Recommendation to Continue Ersodetug Study -- Shares Surge Pre-Bell
Express News | Rezolute Announces Pricing of Offering of $90 Million of Common Stock and Pre-Funded Warrants
what a bunch of bs.